Triple-negative breast
cancer (TNBC) lacks expressed protein targets,
making therapy development challenging. Hydrogels offer a promising
new route in this regard by improving the chemotherapeutic efficacy
through increased solubility and sustained release. Moreover, subcutaneous
hydrogel administration reduces patient burden by requiring less therapy
and shorter treatment times. We recently established the design principles
for the supramolecular assembly of single-domain coiled-coils into
hydrogels. Using a modified computational design algorithm, we designed
Q8, a hydrogel with rapid assembly for faster therapeutic hydrogel
preparation. Q8 encapsulates and releases doxorubicin (Dox), enabling
localized sustained release via subcutaneous injection. Remarkably,
a single subcutaneous injection of Dox-laden Q8 (Q8•Dox) significantly
suppresses tumors within just 1 week. This work showcases the bottom-up
engineering of a fully protein-based drug delivery vehicle for improved
TBNC treatment via noninvasive localized therapy.